Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 12, 2017

Primary Completion Date

May 1, 2020

Study Completion Date

May 1, 2020

Conditions
Urothelial CarcinomaBladder CancerTransitional Cell Carcinoma
Interventions
DRUG

nab-paclitaxel

"Induction: 125 mg/m² by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles to be given with Gemcitabine.~Maintenance: single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."

DRUG

Gemcitabine

Induction: 1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles.

Trial Locations (5)

33401

Florida Cancer Specialists-East, West Palm Beach

33705

Florida Cancer Specialists-North, St. Petersburg

33916

Florida Cancer Specialists - South, Fort Myers

37203

Tennessee Oncology, Nashville

76104

Center for Cancer and Blood Disorders, Fort Worth

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER